Dysregulation of miRNA-21 and their potential as biomarkers for the diagnosis of cervical cancer.
OBJECTIVE
This study aimed to characterize the miR-21 and evaluated its clinical significance.


METHODS
Total RNA was extracted from 30 pairs of fresh specimens of cervical cancer and normal tissues. The expression levels of the miR-21-3p and miR-21-5p were detected by quantitative reverse transcriptase polymerase chain reaction, with U6 as the internal reference gene. We compared the expression of miR-21-3p and miR-21-5p between study group and control groups, the association between miRNA expression level and clinicopathological factors was investigated.


RESULTS
The expression of miR-21-3p and miR-21-5p in HPV positive cervical cancer samples was significantly upregulated compared to that in the paired normal samples (P < 0.05); A multivariate analysis demonstrated that the expression of miR-21 was associated with clinicopathological parameters, including depth of invasion and lymph node metastasis.


CONCLUSIONS
MiR-21 upregulation is associated with aggressive progression and poor prognosis in cervical cancer, which suggests that miR-21 might be identified as an independent marker for predicting the clinical outcome of cervical cancer patients.
Department of Obstetrics and Gynecology, Fengxian Hospital, Southern Medical University Shanghai 201499, P. R. China.
Ying
Y
Han
Department of Obstetrics and Gynecology, Fengxian Hospital, Southern Medical University Shanghai 201499, P. R. China.
Guang-Xu
GX
Xu
Department of Obstetrics and Gynecology, Fengxian Hospital, Southern Medical University Shanghai 201499, P. R. China.
Huan
H
Lu
Department of Obstetrics and Gynecology, Fengxian Hospital, Southern Medical University Shanghai 201499, P. R. China.
Dan-Hua
DH
Yu
Obstetrics and Gynecology Hospital, Fudan University Shanghai 200011, P. R. China ; Changzhou Maternal And Child Health Care Hospital 213003 Jiangsu, P. R. China.
Yuan
Y
Ren
Changzhou Maternal And Child Health Care Hospital 213003 Jiangsu, P. R. China.
Li
L
Wang
Department of Obstetrics and Gynecology, Fengxian Hospital, Southern Medical University Shanghai 201499, P. R. China.
Xu-Hong
XH
Huang
Department of Obstetrics and Gynecology, Fengxian Hospital, Southern Medical University Shanghai 201499, P. R. China.
Wen-Jing
WJ
Hou
Department of Obstetrics and Gynecology, Fengxian Hospital, Southern Medical University Shanghai 201499, P. R. China.
Zhen-Hong
ZH
Wei
Department of Obstetrics and Gynecology, Fengxian Hospital, Southern Medical University Shanghai 201499, P. R. China.
Yuan-Ping
YP
Chen
Shanghai Jiading Maternal and Child Health Care Hospital Shanghai 201899, P. R. China.
Yun-Gui
YG
Cao
Department of Obstetrics and Gynecology, Fengxian Hospital, Southern Medical University Shanghai 201499, P. R. China.
Rong
R
Zhang
D000328:Adult; D014408:Biomarkers, Tumor / Q000235:genetics*; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D005820:Genetic Testing / Q000379:methods; D006801:Humans; D008207:Lymphatic Metastasis; D035683:MicroRNAs / Q000235:genetics*; D008875:Middle Aged; D015999:Multivariate Analysis; D009361:Neoplasm Invasiveness; D011237:Predictive Value of Tests; D011379:Prognosis; D016016:Proportional Hazards Models; D020133:Reverse Transcriptase Polymerase Chain Reaction; D012307:Risk Factors; D015854:Up-Regulation; D002583:Uterine Cervical Neoplasms / Q000175:diagnosis* / Q000235:genetics* / Q000473:pathology / Q000628:therapy
D014408:Biomarkers, Tumor; C524940:MIRN21 microRNA, human; D035683:MicroRNAs
biomarker; cervical cancer; miRNA-21